Related Experiment Video
Updated: May 26, 2025

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase
Claire Louise Kelly1,2, Martyna Wydrzynska2, Marie M Phelan3
1Centre for Preclinical Imaging, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3BX, UK.
Abstract:
Background: Elevated choline kinase alpha (ChoK) levels are observed in most solid tumors, including glioblastomas (GBM), and ChoK inhibitors have demonstrated limited efficacy in GBM models. Given that hypoxia is associated with resistance to GBM therapy, we hypothesized that tumor hypoxia could be responsible for the limited response. Therefore, we evaluated the effects of hypoxia on the function of JAS239, a potent ChoK inhibitor in four GBM cell lines. Methods: Rodent (F98 and 9L) and human (U-87 MG and U-251 MG) GBM cell lines were subjected to 72 h of hypoxic conditioning and treated with JAS239 for 24 h. NMR metabolomic measurements and analyses were performed to evaluate the signaling pathways involved. In addition, cell proliferation, cell cycle progression, and cell invasion parameters were measured in 2D cell monolayers as well as in 3D cell spheroids, with or without JAS239 treatment, in normoxic or hypoxic cells to assess the effect of hypoxia on JAS239 function. Results: Hypoxia and JAS239 treatment led to significant changes in the cellular metabolic pathways, specifically the phospholipid and glycolytic pathways, associated with a reduction in cell proliferation via induced cell cycle arrest. Interestingly, JAS239 also impaired GBM invasion. However, effects from JAS239 were variable depending on the cell line, reflecting the inherent heterogeneity of GBMs. Conclusions: Our findings indicate that JAS239 and hypoxia can deregulate cellular metabolism, inhibit cell proliferation, and alter cell invasion. These results may be useful for designing new therapeutic strategies based on ChoK inhibition, which can act on multiple pro-tumorigenic features.
Insights
Hypoxia impacts glioblastoma treatment by affecting cellular metabolism and proliferation. JAS239, a choline kinase alpha inhibitor, shows potential against GBM, but its efficacy varies with cell line and oxygen levels.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Elevated choline kinase alpha (ChoK) is common in solid tumors like glioblastoma (GBM).
- ChoK inhibitors have shown limited efficacy in GBM models.
- Tumor hypoxia may contribute to therapeutic resistance in GBM.
Purpose of the Study:
- To investigate the impact of hypoxia on the efficacy of JAS239, a potent ChoK inhibitor.
- To evaluate how hypoxia affects GBM cell proliferation, cell cycle, invasion, and metabolic pathways under JAS239 treatment.
Main Methods:
- Utilized four GBM cell lines (rodent and human) under hypoxic conditions.
- Treated cells with JAS239 and analyzed metabolic pathways using NMR.
- Assessed cell proliferation, cell cycle, and invasion in 2D and 3D cultures.
Main Results:
- Hypoxia and JAS239 altered phospholipid and glycolytic pathways.
- JAS239 reduced GBM cell proliferation by inducing cell cycle arrest.
- JAS239 also inhibited GBM cell invasion, though effects varied by cell line.
Conclusions:
- JAS239 and hypoxia can deregulate GBM cellular metabolism, inhibit proliferation, and alter invasion.
- Findings suggest potential for novel therapeutic strategies using ChoK inhibition for GBM.
- Results highlight the need to consider tumor hypoxia in GBM treatment design.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...